Etelcalcetide Reduces PTH Levels in Moderate to Severe SHPT
Etelcalcetide effectively reduces parathyroid hormone (PTH) levels in patients with poorly controlled secondary hyperparathyroidism (SHPT), according to 3 new studies published in Journal of the American Medical Association. The intravenous (IV), second-generation calcimimetic was recently approved in Europe and is currently under review by the FDA...

http://www.renalandurologynews.com/secondary-hyperparathyroidism/secondary-hyperparathyroidism-iv-etelcalcetide-reduces-parathyroid-hormone/article/630864/
Like
Comment
Share